Cargando…
ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression
Ferroptosis is a novel type of programmed cell death that differs from apoptosis in that it involves iron-dependent peroxidation of membrane phospholipids. Its role in a variety of human disorders, including cancer has been hypothesized in recent years. While it may function as an endogenous tumor s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376109/ https://www.ncbi.nlm.nih.gov/pubmed/35963845 http://dx.doi.org/10.1038/s41419-022-05137-5 |
_version_ | 1784768092793995264 |
---|---|
author | Grube, Julia Woitok, Marius Maximilian Mohs, Antje Erschfeld, Stephanie Lynen, Celina Trautwein, Christian Otto, Tobias |
author_facet | Grube, Julia Woitok, Marius Maximilian Mohs, Antje Erschfeld, Stephanie Lynen, Celina Trautwein, Christian Otto, Tobias |
author_sort | Grube, Julia |
collection | PubMed |
description | Ferroptosis is a novel type of programmed cell death that differs from apoptosis in that it involves iron-dependent peroxidation of membrane phospholipids. Its role in a variety of human disorders, including cancer has been hypothesized in recent years. While it may function as an endogenous tumor suppressor in a variety of cancers, its role during initiation and progression of liver cancer, particularly hepatocellular carcinoma (HCC), is yet unknown. Because HCC is most commonly found in chronically injured livers, we utilized two well-established mouse models of chronic injury-dependent HCC formation: Treatment with streptozotocin and high-fat diet as metabolic injury model, as well as treatment with diethylnitrosamine and carbon tetrachloride as toxic injury model. We used mice with hepatocyte-specific deletion of Acsl4, a key mediator of ferroptosis, to explore the significance of ferroptotic cell death in hepatocytes, the cell type of origin for HCC. Surprisingly, preventing ferroptotic cell death in hepatocytes by deleting Acsl4 does not increase the formation of HCC. Furthermore, Acsl4-deficient livers display less fibrosis and proliferation, especially in the HCC model of toxic damage. Intriguingly, in this model, the absence of ACSL4-dependent processes such as ferroptosis significantly slow down the growth of HCC. These findings suggest that during HCC formation in a chronically injured liver, ferroptotic cell death is not an endogenous tumor-suppressive mechanism. Instead, we find that ACSL4-dependent processes have an unanticipated cancer-promoting effect during HCC formation, which is most likely due to aggravated liver damage as demonstrated by increased hepatic fibrosis. Previous studies suggested that ferroptosis might have beneficial effects for patients during HCC therapy. As a result, during HCC progression and therapy, ferroptosis may have both cancer-promoting and cancer-inhibitory effects, respectively. |
format | Online Article Text |
id | pubmed-9376109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-93761092022-08-15 ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression Grube, Julia Woitok, Marius Maximilian Mohs, Antje Erschfeld, Stephanie Lynen, Celina Trautwein, Christian Otto, Tobias Cell Death Dis Article Ferroptosis is a novel type of programmed cell death that differs from apoptosis in that it involves iron-dependent peroxidation of membrane phospholipids. Its role in a variety of human disorders, including cancer has been hypothesized in recent years. While it may function as an endogenous tumor suppressor in a variety of cancers, its role during initiation and progression of liver cancer, particularly hepatocellular carcinoma (HCC), is yet unknown. Because HCC is most commonly found in chronically injured livers, we utilized two well-established mouse models of chronic injury-dependent HCC formation: Treatment with streptozotocin and high-fat diet as metabolic injury model, as well as treatment with diethylnitrosamine and carbon tetrachloride as toxic injury model. We used mice with hepatocyte-specific deletion of Acsl4, a key mediator of ferroptosis, to explore the significance of ferroptotic cell death in hepatocytes, the cell type of origin for HCC. Surprisingly, preventing ferroptotic cell death in hepatocytes by deleting Acsl4 does not increase the formation of HCC. Furthermore, Acsl4-deficient livers display less fibrosis and proliferation, especially in the HCC model of toxic damage. Intriguingly, in this model, the absence of ACSL4-dependent processes such as ferroptosis significantly slow down the growth of HCC. These findings suggest that during HCC formation in a chronically injured liver, ferroptotic cell death is not an endogenous tumor-suppressive mechanism. Instead, we find that ACSL4-dependent processes have an unanticipated cancer-promoting effect during HCC formation, which is most likely due to aggravated liver damage as demonstrated by increased hepatic fibrosis. Previous studies suggested that ferroptosis might have beneficial effects for patients during HCC therapy. As a result, during HCC progression and therapy, ferroptosis may have both cancer-promoting and cancer-inhibitory effects, respectively. Nature Publishing Group UK 2022-08-13 /pmc/articles/PMC9376109/ /pubmed/35963845 http://dx.doi.org/10.1038/s41419-022-05137-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Grube, Julia Woitok, Marius Maximilian Mohs, Antje Erschfeld, Stephanie Lynen, Celina Trautwein, Christian Otto, Tobias ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression |
title | ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression |
title_full | ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression |
title_fullStr | ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression |
title_full_unstemmed | ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression |
title_short | ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression |
title_sort | acsl4-dependent ferroptosis does not represent a tumor-suppressive mechanism but acsl4 rather promotes liver cancer progression |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376109/ https://www.ncbi.nlm.nih.gov/pubmed/35963845 http://dx.doi.org/10.1038/s41419-022-05137-5 |
work_keys_str_mv | AT grubejulia acsl4dependentferroptosisdoesnotrepresentatumorsuppressivemechanismbutacsl4ratherpromoteslivercancerprogression AT woitokmariusmaximilian acsl4dependentferroptosisdoesnotrepresentatumorsuppressivemechanismbutacsl4ratherpromoteslivercancerprogression AT mohsantje acsl4dependentferroptosisdoesnotrepresentatumorsuppressivemechanismbutacsl4ratherpromoteslivercancerprogression AT erschfeldstephanie acsl4dependentferroptosisdoesnotrepresentatumorsuppressivemechanismbutacsl4ratherpromoteslivercancerprogression AT lynencelina acsl4dependentferroptosisdoesnotrepresentatumorsuppressivemechanismbutacsl4ratherpromoteslivercancerprogression AT trautweinchristian acsl4dependentferroptosisdoesnotrepresentatumorsuppressivemechanismbutacsl4ratherpromoteslivercancerprogression AT ottotobias acsl4dependentferroptosisdoesnotrepresentatumorsuppressivemechanismbutacsl4ratherpromoteslivercancerprogression |